Answers are grounded in this paper and cite their sources.
This research uncovers a new radioligand for effective cancer imaging, suggesting a novel pathway for therapy.
Background: Ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) represents a promising target for cancer therapy due to its overexpression in various solid tumors, specifically hepatocellular carcinoma, renal cell carcinoma, prostate cancer, colorectal carcinoma and ovarian cancer. Several high affinity bispecific antibodies and ADCs targeting ENPP3 are currently in clinical development thereby demonstrating the clinical translatability of this target. Radioligand therapy (RLT) has demonstrated tremendous potential to improve survival in cancer patients with limited or ineffective treatment options. Herein, we report the discovery of a first-in-class small molecule radioligand (68Ga-AVA-ERL) for high ENPP3 tumors imaging that can form the basis for further development of ENPP3-targeted radiotherapeutics. Methods: ENPP3 ligands generated from in-house libraries were conjugated with dye or DOTA (followed by radiolabeling with 68Ga). Target engagement (affinity and specificity) studies with Cy5 labelled AVA-ERL compounds were carried out to confirm in vitro binding using both high (HepG2) and low (MDA-MB-231) ENPP3-expressing cell lines. In vivo fluorescence imaging (IVIS) and ex vivo tissue analysis of Cy5 labelled AVA-ERL compounds was carried out in nude mice bearing HepG2 tumor to confirm target specificity. Imaging studies with 68Ga-AVA-ERL compounds was further carried out in HepG2 tumors. Results: We have developed a library of AVA-ERL compounds (dye and radiolabelled) targeting ENPP3. Upon screening this library for in vitro and in vivo binding assay, pharmacokinetic profiling and biodistribution studies, we identified the lead ligands suitable for 68Ga based imaging studies. Our novel first-in-class ENPP3 targeted RLT has demonstrated efficient target engagement, high tumor uptake and a favourable biodistribution profile. Conclusions: To our knowledge, the compounds described here are the first disclosure of small molecule ligands targeting ENPP3 for radiotheranostics. Dye and radiolabelled AVA-ERL-compounds have demonstrated a favourable pharmacokinetic profile and efficient target engagement. Our findings demonstrate the potential of a first-in-class ENPP3 targeted radioligand for imaging that can form the basis for the development of potentially effective radioligand therapeutics for HCC. Citation Format: Aditya Kulkarni, Sandeep Goyal, Avijit Goswami, Kawaljit Singh, Princy Khurana, Srinivasarao Madduri. Development of a first-in-class ENPP3-targeted radioligand for liver and renal cancer imaging [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5808.
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: